Millennium Management’s Vaxcyte PCVX Stock Holding History

Millennium Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-31,200	Closed	-$1.01M	–	6355
2025 Q2	$1.01M	Buy	31,200 +1,200	+4%	+$39.3K	﹤0.01%	4395
2025 Q1	$1.13M	Buy	+30,000	New	+$2.4M	﹤0.01%	4254
2023 Q3	–	Sell	-10,000	Closed	-$499K	–	6442
2023 Q2	$499K	Buy	+10,000	New	+$474K	﹤0.01%	4548

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Millennium Management's PCVX Position: Q2 2026 in Review

Millennium Management reduced its Vaxcyte (PCVX) stake by 53% in Q2 2026, selling an estimated $8.53M and leaving 136,625 shares worth $7.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2541.

Millennium Management first reported a position in PCVX in Q2 2020 and has held it in 25 quarters since. The position peaked at $60.6M in Q2 2023. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Millennium Management held 136,625 shares of Vaxcyte worth $7.94M as of Q2 2026.
Millennium Management sold 157,070 Vaxcyte shares in Q2 2026, an estimated $8.53M.
Vaxcyte made up ﹤0.01% of Millennium Management's portfolio in Q2 2026, its #2541 holding.
Millennium Management first reported a position in Vaxcyte in Q2 2020 and has held it in 25 quarters since.
Millennium Management's Vaxcyte position peaked at $60.6M in Q2 2023.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.